Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
38.02
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
104
Open
38.02
Bid (Size)
37.13 (1)
Ask (Size)
38.60 (1)
Prev. Close
38.02
Today's Range
38.02 - 38.02
52wk Range
29.85 - 45.00
Shares Outstanding
142,334,900
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
9 Analysts Have This To Say About Halozyme Therapeutics
April 16, 2024
Via
Benzinga
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
April 16, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Via
Chartmill
Performance
YTD
+1.68%
+1.68%
1 Month
-5.82%
-5.82%
3 Month
+5.49%
+5.49%
6 Month
+5.85%
+5.85%
1 Year
+6.47%
+6.47%
More News
Read More
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
April 09, 2024
Via
Benzinga
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
April 05, 2024
Via
Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
April 02, 2024
Via
Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
February 21, 2024
Via
Chartmill
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
February 21, 2024
Via
Benzinga
Halozyme Therapeutics: Q4 Earnings Insights
February 20, 2024
Via
Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
March 29, 2024
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
Via
Investor's Business Daily
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
March 14, 2024
Via
Chartmill
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
March 13, 2024
Via
InvestorPlace
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
March 11, 2024
Via
Chartmill
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
March 01, 2024
Via
Chartmill
Earnings Preview: Halozyme Therapeutics
February 19, 2024
Via
Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
February 19, 2024
Via
Chartmill
NASDAQ:HALO, an undervalued stock with good fundamentals.
February 09, 2024
Via
Chartmill
Earnings Scheduled For February 20, 2024
February 20, 2024
Via
Benzinga
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
February 15, 2024
Via
Benzinga
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
January 31, 2024
Via
Chartmill
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
January 29, 2024
Via
Benzinga
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
January 29, 2024
Via
Chartmill
3 Biotech Stocks to Sell in January Before They Crash and Burn
January 25, 2024
Via
InvestorPlace
NASDAQ:HALO: good value for what you're paying.
January 19, 2024
Via
Chartmill
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
January 18, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.